Reversal of docetaxel resistance with bevacizumab and thalidomide

Yang Min Ning, William Figg, William Dahut*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Taxane resistance is a common clinical problem in the treatment of many metastatic malignancies. Observational clues or evidence of overcoming such resistance is important for developing treatments that can extend taxane activity. We report a case of the reversal of docetaxel resistance with the addition of antiangiogenic agents bevacizumab and thalidomide to docetaxel and prednisone in a patient with metastatic castration-resistant prostate cancer after PSAWG progression on docetaxel and prednisone. The patient then responded for an additional 7 months. The addition of bevacizumab and thalidomide after progression on docetaxel/prednisone might reverse docetaxel resistance. These or other antiangiogenic agents for overcoming clinical taxane resistance are candidates for further study.

Original languageEnglish
Pages (from-to)E37-E38
JournalClinical Genitourinary Cancer
Issue number2
StatePublished - 2009
Externally publishedYes


  • Antiangiogenesis
  • Castration-resistant prostate cancer
  • Reversal of taxane resistance


Dive into the research topics of 'Reversal of docetaxel resistance with bevacizumab and thalidomide'. Together they form a unique fingerprint.

Cite this